This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Resumen de acción MYOV
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Competidores de Myovant Sciences Ltd.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.98 |
| 52 Week High | US$27.06 |
| 52 Week Low | US$7.67 |
| Beta | 2.15 |
| 1 Month Change | 0.26% |
| 3 Month Change | 0.41% |
| 1 Year Change | 125.40% |
| 3 Year Change | 278.93% |
| 5 Year Change | 44.51% |
| Change since IPO | 103.47% |
Noticias y actualizaciones recientes
Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M
Jan 26Not The Buyout Offer That Myovant Shareholders Hoped For
Oct 25Recent updates
Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M
Jan 26Not The Buyout Offer That Myovant Shareholders Hoped For
Oct 25Myovant Sciences rejects Sumitovant Biopharma's $22.75/share takeover offer
Oct 03Women Can Thank Pfizer And Myovant For MYFEMBREE
Sep 20Myovant Sciences: Regulatory Overhang Cleared
Aug 29Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication
Aug 09Myovant stock gains ~6% after hours on Q1 revenue jump
Jul 27Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree
Jul 18Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher
Apr 28
Myovant: Poised To Overcome Regulatory Issues
Apr 26Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels
Apr 13Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play
Mar 26Myovant: Catalysts Powering More Upside
Jan 02Myovant Sciences: Becoming A Blockbuster
Jun 02Myovant Sciences rises on FDA approval for relugolix
May 26Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates
May 14Why The Misunderstood Pfizer Deal Makes Myovant A Great Low-Risk Investment
May 09New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)
Feb 17Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates
Feb 13Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher
Jan 12Myovant cut to neutral at Goldman Sachs on ‘lack of driving catalysts’
Jan 06Myovant Sciences announces distribution of ORGOVYX in the U.S.
Jan 05Myovant Sciences gains 22% on relugolix deal with Pfizer
Dec 28Have Insiders Been Selling Myovant Sciences Ltd. (NYSE:MYOV) Shares This Year?
Dec 23
Myovant Sciences’ FDA win leads to Bullish views at Baird
Dec 21Myovant Sciences scores FDA approval for Orgovyx in prostate cancer
Dec 18Myovant Sciences (NYSE:MYOV) Shareholders Have Enjoyed A 60% Share Price Gain
Nov 18Myovant Sciences: More Than Meets The Eye
Nov 12The Sell-Off In Myovant Is Unjustified By Fundamentals
Nov 09Rentabilidad de los accionistas
| MYOV | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 0.1% | 4.7% | 0.7% |
| 1Y | 125.4% | 2.7% | 23.9% |
Rentabilidad vs. Industria: MYOV exceeded the US Biotechs industry which returned 2.8% over the past year.
Rentabilidad vs. Mercado: MYOV exceeded the US Market which returned -9.9% over the past year.
Volatilidad de los precios
| MYOV volatility | |
|---|---|
| MYOV Average Weekly Movement | 0.3% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: MYOV has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: MYOV's weekly volatility has decreased from 11% to 0% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2016 | 579 | Dave Marek | myovant.com |
Resumen de fundamentos de Myovant Sciences Ltd.
| Estadísticas fundamentales de MYOV | |
|---|---|
| Capitalización bursátil | US$2.62b |
| Beneficios(TTM) | -US$183.77m |
| Ingresos (TTM) | US$379.11m |
6.9x
Ratio precio-ventas (PS)-14.3x
Ratio precio-beneficio (PE)¿Está MYOV sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de MYOV | |
|---|---|
| Ingresos | US$379.11m |
| Coste de los ingresos | US$209.66m |
| Beneficio bruto | US$169.45m |
| Otros gastos | US$353.22m |
| Beneficios | -US$183.77m |
Últimos beneficios comunicados
Dec 31, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.89 |
| Margen bruto | 44.70% |
| Margen de beneficio neto | -48.47% |
| Ratio deuda/patrimonio | -64.3% |
¿Cómo se ha desempeñado MYOV a largo plazo?
Ver rendimiento histórico y comparativa